AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02451345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized risk model+website+coaching intervention
Description: A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care.
Study NCT01804959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx probiotics
Study NCT01804959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vivomixx probiotics
Study NCT02448303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02448303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study NCT00630877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin extended-release (NER)
Description: Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
Study NCT00630877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin extended-release (NER) placebo
Description: Tablets administered once daily for 6 weeks
Study NCT00630877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Description: Tablets (325 mg) administered once daily for 6 weeks
Study NCT00630877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) placebo
Description: Tablets administered once daily for 6 weeks
Study NCT03616210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protective ventilation
Description: Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
Study NCT04599881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTR-01
Description: IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
Study NCT02657850 — intervention group
Intervention type: OTHER
Intervention: non- head and neck self reporting
Description: non- head and neck patient self reports dysphagia symptoms
Study NCT02657850 — intervention group
Intervention type: OTHER
Intervention: head neck self reporting
Description: head and neck patient self reports dysphagia symptoms
Study NCT02657850 — intervention group
Intervention type: OTHER
Intervention: provider reporting
Description: provider reports on head and neck cancer patients' dysphagia symptoms
Study NCT06454513 — intervention group
Intervention type: PROCEDURE
Intervention: general anesthesia
Description: Different anesthesia methods
Study NCT01963689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intervention Group 2
Description: Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
Study NCT01963689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group 1
Description: Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
Study NCT01963689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group 3
Description: Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
Study NCT01428492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
Study NCT01428492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
Study NCT01406769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT01406769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical vulvectomy or radical local excision
Study NCT01818219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Records of EADI derived parameters
Study NCT00486213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pyridoxine hydrochloride
Description: Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
Study NCT01428492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
Study NCT02661906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKY
Description: Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
Study NCT02661906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SKY
Description: Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
Study NCT01690403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine (M000473)
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01690403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFZ EMT TDF
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT04946513 — intervention group
Intervention type: OTHER
Intervention: Muscle volumes were measured on pre- and postoperative MRI scans.
Description: Muscle volumes were measured on pre- and postoperative MRI scans.
Study NCT02294292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
Study NCT02294292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction
Study NCT02294292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 100 micrograms
Description: Tablets were taken under fasted conditions with non-carbonated water.
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol 400 micrograms
Description: Tablets were taken under fasted conditions with non-carbonated water.
Study NCT00486213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone hydrochloride 4 milligrams
Description: Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Study NCT01035593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis and IVIG
Description: Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
Study NCT01035593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant C1 inhibitor
Description: 100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
Study NCT01779349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Urine Vibration Holter
Description: each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study
Study NCT03930056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Brace II
Description: Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
Study NCT03930056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Care KAFO intervention
Description: Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
Study NCT03327701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching hydromorphone
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Study NCT03327701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benralizumab
Description: Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching cebranopadol
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
Study NCT03757559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching cebranopadol
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
Study NCT06054646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amnion collagen
Description: A collagen extract sourced from the human amniotic membrane
Study NCT06054646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: Autologous preparation of PRP
Study NCT01543256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered Stent System RMV
Description: Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell. (RMV in intervention name indicates removable)
Study NCT01543256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Plastic Stent Per Investigator preference
Description: Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
Study NCT01764100 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
Study NCT04506450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve block
Description: In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during hip surgery.~Lumbar plexus and sciatic nerve blocks will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle and plantar or dorsal flexion of the foot will be detected respectively. For both, a mixture of mepivacaine and levobupivacaine will be injected.~Lateral femoral cutaneous nerve block will be performed with the ultrasound technique. After identifying the nerve, a needle will be inserted with an in plane approach and will be injected.~Lateral branch of iliohypogastric nerve block will be executed with the De Visme approach. Along the iliac crest (range between 7 and 11 cm from the anterior superior iliac spine) a needle will be inserted until bone contact is found. Then a mixture of mepivacaine and levobupivacaine will be injected.
Study NCT04506450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: In this group, spinal anesthesia will be performed to ensure anesthesia during surgery, while lumbar plexus block will be performed to ensure postoperative analgesia Spinal anesthesia will be performed with a 25 G needle and 12 mg 0.5% levobupivacaine will be injected.~Lumbar plexus block will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the femoral quadriceps muscle will be detected. 20 ml 0.5% levobupivacaine will be injected.
Study NCT02855294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COC containing 30 μg of EE and 3mg of drospirenone
Description: treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
Study NCT01787604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Root Reimplantation Procedure
Description: Modified Florida Sleeve.
Study NCT01787604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Valve Reimplantation Procedure
Description: David I
Study NCT01466816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test meals with various fatty acid compositions
Description: Three different milkshakes with a U13C palmitate tracer added
Study NCT03229330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-level Light Therapy
Description: Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
Study NCT03229330 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
Study NCT03229330 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
Study NCT03773744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-MAGEA3
Description: Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Study NCT03773744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG1-MAGEA3
Description: MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Study NCT03773744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: monoclonal antibody; checkpoint inhibitor of PD1
Study NCT03773744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: low-dose chemotherapy
Study NCT02227160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 weekly group meetings
Description: 10 weekly group meetings with up to five other men and women at Grady Health System
Study NCT02227160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient counseling and support groups
Description: Usual mental health care
Study NCT02227160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient counseling and support groups
Description: Usual mental health care
Study NCT02318329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPA144
Description: FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 IV, given day 1
Study NCT06702540 — intervention group
Intervention type: DEVICE
Intervention: Biosensor chip
Description: An electronic platform measuring the impedance variation between microelectrodes is used upon capturing the target biomolecule by a selective bioprobe previously grafted over the biosensor surface. The required sensitivity will be achieved by operating the biosensor in lock-in mode, which ensures the highest resolution in tracking amplitude and phase variations of impedance signals.
Study NCT02300064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee-extensor exercise test
Description: Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
Study NCT04578548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG2737
Description: Capsules administered orally
Study NCT04578548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG2737
Description: Capsules administered orally
Study NCT04578548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered orally
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 IV, given day 1
Study NCT01679119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4mg/m2(max 2mg)IV given day 1
Study NCT03608072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: 3 sequential dose groups
Study NCT03608072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 sequential dose groups
Study NCT00555399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days.
Study NCT00555399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Phase I/Arm 1: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m\^2/day PO x 21 days; Level -I = 100 mg/m\^2/day PO x 21 days; Level 0 = 100 mg/m\^2/day PO x 21 days; Level I = 100 mg/m\^2/day PO x 21 days; Level II = 100 mg/m\^2/day PO x 21 days.
Study NCT00555399 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: Surgical Resection for recurrent Glioblastoma Multiforme
Study NCT00555399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days.